Speaker(s): 

Kathie Wu, DO, PGY4 Hematology/Oncology Fellow, Geisinger - has nothing to disclose.

Jonathan "Ryan" Lozano, PharmD, PGY2 Oncology Pharmacy Resident, Geisinger - has nothing to disclose.

Moderator(s): 

Tristan Maiers, PharmD, BCOP, PGY2 Oncology Residency Program Director, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

•Describe pathophysiology and disease states treatable with bone modifying agents (BMAs)
•Compare types of BMAs and the mechanisms behind their utility in oncology
•Discuss clinical considerations prior to initiation and during treatment with BMAs
•Analyze current BMA practice guidelines

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Tristan Maiers, PharmD, BCOP, Rajiv Panikkar, MD, Michele Long, BSN, Jaime Weeder, NP and Christopher Kashi, PA-C have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.

Session date: 
11/26/2024 - 12:00pm to 1:00pm EST
Location: 
Geisinger Medical Center
100 North Academy Ave.
Knapper Clinic
Danville, PA 17822
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AAPA Category I CME
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation Credit

Please login or register to take this course.